MORGAN STANLEY PLC/CALL/GILEAD SCIENCES/87.5/0.1/20.12.24

MORGAN STANLEY PLC/CALL/GILEAD SCIENCES/87.5/0.1/20.12.24 Stock

DE000MB331D7

Real-time Bid/Ask 01:10:19 2024-06-28 pm EDT
0.082 ^EUR / 0.085 ^EUR	-4.55%

Current month	+131.58%
1 month	+137.84%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart GILEAD SCIENCES, INC.

Chart MORGAN STANLEY PLC/CALL/GILEAD SCIENCES/87.5/0.1/20.12.24

Latest news about GILEAD SCIENCES, INC.

Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia	Jun. 26	CI
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $119 From $117	Jun. 26	MT
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer	Jun. 25	CI
Jefferies Adjusts Price Target on Gilead Sciences to $85 From $80	Jun. 24	MT

More news

Quotes 5-day view

Date	Price	Change
24-06-28	0.086	-2.27%
24-06-27	0.088	-5.38%
24-06-26	0.093	-8.82%
24-06-25	0.102	-19.69%
24-06-24	0.127	+3.25%

Delayed Quote Börse Stuttgart

Last update June 28, 2024 at 08:45 am EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	GILEAD SCIENCES, INC.
Issuer	Morgan Stanley
WKN	MB331D
ISIN	DE000MB331D7
Date issued	2023-02-01
Strike	87.5 $
Maturity	2024-12-20 (175 Days)
Parity	10 : 1
Emission price	1.21 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.3 €
Lowest since issue	0.03 €
Spread	0.003 €
Spread %	3.53%

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

More about the company

Ratings for Gilead Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Consensus: Gilead Sciences, Inc.

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

68.83 USD

Average target price

82.97 USD

Spread / Average Target

+20.54%

Consensus